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Abstract
Objective To compare the cost effectiveness of social behaviour
and network therapy, a new treatment for alcohol problems,
with that of the proved motivational enhancement therapy.
Design Cost effectiveness analysis alongside a pragmatic
randomised trial.
Setting Seven treatment sites around Birmingham, Cardiff, and
Leeds.
Participants 742 clients with alcohol problems; 617 (83.2%)
were interviewed at 12 months and full economic data were
obtained on 608 (98.5% of 617).
Main economic measures Quality adjusted life years (QALYs),
costs of trial treatments, and consequences for public sector
resources (health care, other alcohol treatment, social services,
and criminal justice services).
Results Both therapies saved about five times as much in
expenditure on health, social, and criminal justice services as
they cost. Neither net savings nor cost effectiveness differed
significantly between the therapies, despite the average cost of
social behaviour and network therapy (£221; $385; €320) being
significantly more than that of motivational enhancement
therapy (£129). If a QALY were worth £30 000, then the
motivational therapy would have 58% chance of being more
cost effective than the social therapy, and the social therapy
would have 42% chance of being more cost effective than the
motivational therapy.
Conclusion Participants reported highly significant reductions
in drinking and associated problems and costs. The novel social
behaviour and network therapy did not differ significantly in
cost effectiveness from the proved motivational enhancement
therapy.
Introduction
Heavy drinking in England and Wales costs an estimated
£18 000m ($32 438m; €26 424m) each year as a result of costs
for health and social care, losses to productivity, and criminal
activity.1 Treatment for alcohol problems has the potential to
improve the health of alcohol dependent individuals and to
reduce social costs. Reviews of economic analyses of treatment
for alcohol and other substance misuse have consistently found
that health and other social costs decrease after treatment but
have also identified methodological weaknesses.2 3 In particular,
few have collected prospective data alongside randomised
controlled trials.
Modelling of economic costs and consequences, mainly
using expert opinions, and reviews of evidence suggested that
brief motivational counselling, which includes motivational
enhancement therapy, is more cost effective than many other
types of treatment for alcohol problems.4 Modelling of long term
health outcomes suggests that many psychosocial treatments,
including motivational interviewing and training in social skills,
reduce social costs.5
A large randomised trial of alcohol treatments in the United
States (the “matching alcoholism treatments to client heteroge-
neity” trial) generated two economic analyses on completion.6 7
The first study modelled the costs of treatment from data on the
uptake of therapies and calculated that motivational enhance-
ment therapy would be less costly than cognitive behavioural
therapy or twelve step facilitation in non-research settings.6 The
second study analysed the health records of participants and
concluded that healthcare costs decreased after treatment,
confirming the economic benefits of treating alcohol problems.7
The UK alcohol treatment trial provided an opportunity to
collect economic data alongside a large randomised trial.We col-
lected data on general health outcomes, specific drinking
outcomes, and a range of social effects. We designed the
economic analysis to test whether social behaviour and network
therapy, a new social treatment, was as cost effective in improving
quality of life as motivational enhancement therapy, a
motivational treatment of proved effectiveness.We compared the
treatment costs, consequences for public sector resources, and
health outcomes of the two therapies.
Methods
The UK alcohol treatment trial is described in detail elsewhere8
and summarised in the accompanying paper.9 Social behaviour
and network therapy, comprising up to eight 50 minute sessions,
helps clients to build social networks to support change in their
drinking and associated behaviours. Motivational enhancement
therapy, comprising up to three 50 minute sessions, combines
counselling in the motivational style with objective individual
feedback from earlier assessment.
We carried out our trial in seven UK sites around
Birmingham, Cardiff, and Leeds. We trained 72 therapists in
social behaviour and network therapy or motivational enhance-
ment therapy through courses at Leeds lasting three days. To
achieve accreditation the therapists had to show competence
through video recordings and complete the supervised
treatment of at least two clients in the motivational group or one
client in the social network group (since clients in the social net-
work group receive about twice as many sessions as those in the
motivational group). Fifty two therapists achieved such
accreditation. We recruited 742 clients with alcohol problems of
all ages above 16 and from all social groups.
Full authorship details, the collaborators, and a detailed table of resources
and costs are on bmj.com
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We interviewed 617 (83.2%) clients at 12 months. Of 352
clients in the motivational group, 347 (99%) yielded data for eco-
nomic analysis, together with 261 (99%) of 265 clients in the
social network group. We valued all economic costs and
consequences in pounds sterling at 2000-1 prices. Discounting
was not necessary as we measured costs and consequences
occurring within a year of recruiting clients.
Measurement of treatment costs
We measured the time trainers and therapists spent in training
and supervision, and their use of space and materials. We valued
their time from their individual salaries, employers’ costs, and
overheads.10 We spread the total cost for training in each therapy
over the corresponding number of sessions delivered for the UK
alcohol treatment trial.
We measured the time therapists spent in delivering
treatment from forms they completed after each session in each
site, and we valued this time in the same way as the training costs.
We measured the space and other resources therapists used at
individual sites and valued these using local costs. To calculate
the cost of treatment we multiplied session length in minutes by
the cost per minute of the individual therapist and other
resources. We derived the cost of treating each individual by
summing over sessions.
Measurement of public sector resource use
We devised a questionnaire to measure, both at baseline and at
12 months, clients’ use over the previous six months of health
care, alcohol treatment outside our trial, social services, and the
criminal justice system. We chose a period of six months so as to
capture important but infrequent events within clients’ recall. We
estimated the unit costs of the 40 items covered by the question-
naire as long run marginal opportunity costs. Costs of health and
social care items came from a national source,10 costs of crime
came from government sources,11–13 and costs of alcohol
treatment came partly from the UK alcohol treatment trial and
partly from another UK study.5 Table 1 lists the more expensive
resources, together with their average use, unit costs, and sources
(see also table A on bmj.com).
Measurement of health outcomes
To permit comparison with other economic evaluations, we
assessed health outcomes through quality adjusted life years
(QALYs).14 15 We asked participants to complete the EQ-5D ques-
tionnaire at baseline and at three and 12 months.16 This generic
health status instrument measures health on five scales (mobility,
self care, usual activities, pain and discomfort, and anxiety and
depression) each with three points, thus putting participants into
one of 243 ( = 3×3×3×3×3) health states.We estimated how many
QALYs participants had experienced during their year in the UK
alcohol treatment trial by using UK population norms to value
their health states17 and linear interpolation18 to calculate areas
under the QALY curves. To impute missing final health states for a
few respondents we carried forward their previous states.
Economic and statistical analysis
To improve estimates of QALYs we adjusted for differences in
baseline measurements. Under specified assumptions analysis of
covariance yields more precise estimates than analysis of
changes between baseline and follow-up.19 As the economic data
collected in the UK alcohol treatment trial may violate several of
these assumptions, however, it is acceptable and prudent to ana-
lyse changes between baseline and follow-up.20
As the economic data were skewed, we used bootstrapping to
obtain more reliable confidence intervals.21 We used the
statistical package STATA to draw 1000 artificial bootstrapped
samples, each containing 608 observations drawn randomly with
replacement from the actual sample of 608 participants with
complete economic data. This enabled us to derive bootstrapped
confidence intervals for key statistics, notably QALY gains and
savings in public sector resources.We then divided the net cost of
therapy by the QALYs gained to yield the average cost per
QALY, otherwise known as the incremental cost effectiveness
ratio. We estimated the sampling distribution of this ratio from
the 1000 bootstrapped samples and derived cost effectiveness
acceptability curves. These curves plot the resulting probability
that one therapy is better than the other against the maximum
that decision makers might pay for an additional QALY.21















Hospital inpatient Night 242 2.69 (6.85) 2.93 (6.68) 2.14 (10.46) 2.05 (8.89)
Hospital day patient Visit 77 0.04 (0.20) 0.02 (0.16) 0.03 (0.17) 0.03 (0.16)
Hospital outpatient Appointment 74 0.31 (0.70) 0.37 (0.76) 0.47 (1.18) 0.39 (0.98)
Hospital accident and emergency department Visit 61 0.55 (0.83) 0.50 (0.81) 0.28 (0.61) 0.33 (0.71)
General practitioner:
At home Home visit 59 0.12 (0.45) 0.15 (0.46) 0.12 (0.65) 0.12 (0.98)
In surgery Consultation 19 4.05 (4.46) 3.75 (4.16) 3.11 (3.42) 3.84 (4.22)
Prescriptions Prescription 19 11.61 (18.00) 12.39 (17.90) 11.65 (19.80) 11.68 (21.90)
Community psychiatric nurse Home visit 27 0.61 (2.42) 0.96 (3.35) 0.32 (1.08) 0.48 (1.69)
Specialist alcohol treatment
Detoxification in primary care2 Episode 350 0.16 (0.71) 0.18 (0.66) 0.06 (0.47) 0.04 (0.39)
Alcohol agency:
Rehabilitation10 Night 89 0.32 (4.17) 0.24 (2.28) 0.13 (0.97) 0.10 (0.98)
Consultation* Appointment 28 1.83 (2.56) 1.85 (2.37) 1.03 (9.90) 1.33 (7.61)
Social services10 Contact 7 1.51 (3.66) 1.84 (6.16) 1.12 (4.71) 1.06 (3.43)
Criminal justice11
Court attendance:
Crown court Appearance 8824 0.017 (0.131) 0.027 (0.162) 0.020 (0.140) 0.011 (0.107)
Magistrates court attendance Appearance 564 0.21 (0.76) 0.28 (0.79) 0.17 (1.02) 0.16 (0.74)
*Estimated from data in UK alcohol treatment trial (excluding training costs).
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Sensitivity analyses
To test whether differences in treatment costs between social
behaviour and network therapy and motivational enhancement
therapy depended on our assumptions, we undertook three dis-
tinct sensitivity analyses. We spread training costs over all 736
treatment sessions (16 sessions a week for 46 weeks) that a typi-
cal therapist might deliver in a year, rather than just the sessions
therapists delivered within the UK alcohol treatment trial. We
replaced the salaries of all 52 therapists in the UK alcohol treat-
ment trial by the lower quartile of their annual salaries (£21 000
for a general counsellor) and then the higher quartile (£26 000
for a senior nurse). To test the effect of compliance with
treatment we replaced the number of sessions attended for one
treatment by the 10th centile of its distribution and the other by
the 90th centile of its distribution, and vice versa.
Results
The 347 clients in the motivational group reported mean EQ-5D
scores (health utilities) of 0.616 (SD 0.299) at baseline, 0.684 (SD
0.293) at three months, and 0.671 (SD 0.311) at 12 months. The
corresponding values for the 261 clients in the social network
group were 0.589 (SD 0.298), 0.648 (SD 0.314), and 0.626 (SD
0.324). After adjusting for baseline differences, we estimated that
the social network group achieved 0.0113 fewer QALYs than the
motivational group, but this was not significant (bias corrected
95% confidence interval 0.0532 fewer to 0.0235 more).
Treatment costs and resource savings
The average treatment cost of social behaviour and network
therapy (£221) was significantly greater than that of motivational
enhancement therapy (£129; table 2). Three sensitivity analyses
confirm the significantly higher cost of the social therapy (table
2). The difference ranged from £24 when spreading training
costs over all 736 treatment sessions delivered by a typical thera-
pist to £117 when comparing the 10th centile of the number of
sessions for the motivational therapy (1.9) with the 90th centile
of the number of sessions for the social therapy (4.0).
In the six months before randomisation, 590 (97.0%) of 608
participants had used health care and 572 (94.1%) had been in
contact with services providing treatment for alcohol problems,
but only 286 (47.0%) had used social services and only 128
(21.1%) had had any contact with criminal justice. In the six
months before follow-up all these percentages fell: 517 (85.0%)
used health care, only 164 (27.0%) contacted alcohol treatment
services, 170 (28.0%) used social services, and 61 (10.0%) had any
contact with criminal justice. Valuing these differences shows
that both treatments resulted in substantial and similar savings in
public sector resources—namely, about five times as much as they
cost (table 3). Combining treatment costs with these savings sug-
gests that social behaviour and network therapy achieved a mean
net public sector saving of £206 per client more than
motivational enhancement therapy, but the difference was not
significant (95% confidence interval − £454 to £818).








Basic assumptions 129 (58) 221(179) 92 (69 to 113)
Varying spread of training costs:
Spread training costs over 736 treatment sessions that typical therapist delivers per year (16 sessions/week×46
weeks) rather than sessions therapists delivered within UK alcohol treatment trial
63 (26) 87 (77) 24 (15 to 32)
Varying therapists’ salaries:
£20 893 (lower quartile) 127 (57) 208 (161) 80 (62 to 99)
£26 110 (higher quartile) 132 (59) 216 (169) 83 (65 to 103)
Varying compliance with treatment (mean No of sessions):
Motivational sessions 1.89 (10th centile), social sessions 4.01 (90th centile) 123 (18) 241 (39) 117 (112 to 122)
Motivational sessions 2.12 (90th centile), social behaviour sessions 3.27 (10th centile) 135 (18) 200 (34) 64 (60 to 69)
Table 3 Costs of public sector resources at 2000-1 prices by allocated treatment. Values are mean (standard deviation) costs of alcohol problems unless
stated otherwise







Six months before randomisation:
Health care 1121 (1953) 1192 (1829) 71 (−219 to 389)
Criminal justice 519 (1524) 685 (1823) 166 (−104 to 466)
Other alcohol treatment 502 (1456) 621 (1071) 119 (−103 to 299)
Social care 50 (133) 87 (303) 37 (3 to 84)*
Total 2192 (3409) 2585 (3224) 393 (−118 to 918)
Six months before follow-up:
Health care 900 (2693) 912 (2330) 13 (−419 to 379)
Criminal justice 351 (1851) 301 (1241) −50 (−315 to 181)
Other alcohol treatment 186 (806) 290 (1037) 104 (−31 to 271)
Social care 34 (107) 63 (208) 29 (3 to 58)*
Total 1469 (3466) 1565 (3171) 96 (−435 to 602)
Reduction in public sector resources: 6 months before randomisation versus 6 months before follow-up 722 (4116) 1020 (3802) 298 (−353 to 909)
Cost of specialist alcohol treatment within trial 129 (58) 221 (178) 92 (69 to 113)**
Net reduction in public sector resource costs minus cost of trial treatments 593 (4114) 798 (3817) 206 (−454 to 818)
*Statistically significant difference between treatments at 5% level.
†Confidence interval corrected for bias.
***Statistically significant difference between treatments at 0.1% level.
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Cost utility analysis
Combining the net savings from social behaviour and network
therapy with the net health utility gains it achieved yields an
incremental cost effectiveness ratio which is the ratio of two
negative but non-significant quantities. To summarise this double
negative, motivational enhancement therapy has an incremental
cost effectiveness ratio of £18 230 (marginal cost of £206 divided
by marginal utility gain of 0.0113) relative to the social therapy.
Bootstrapping generated 1000 different artificial samples to
characterise the distribution of health outcomes and net costs
(treatment costs less public sector savings) between the two
treatments. In 233 samples social behaviour and network therapy
was more effective than motivational enhancement therapy in
generating QALYs and less costly in net public sector resources
(social therapy dominated motivational therapy). In 193 the social
therapy was more costly and less effective than the motivational
therapy (motivational therapy dominated social therapy). In 514
the social therapy was less costly but less effective than the motiva-
tional therapy, and in the remaining 60 the social therapy was
more effective but more costly than the motivational therapy. Thus
19% of bootstrapped samples unequivocally favoured motiva-
tional enhancement therapy whereas 23% unequivocally favoured
social behaviour and network therapy—a difference of only 4%.
Plotting the resulting probability that the motivational
therapy is more cost effective than the social therapy against the
maximum that decision makers might pay for a QALY shows
that the two therapies were similarly cost effective (figure). When
this threshold is small, the social therapy seems preferable to the
motivational therapy. For example, when a QALY is worth noth-
ing to decision makers, the social therapy would be preferable to
the motivational therapy in 747 (74.7%) of the 1000 samples
(514 where the health gain from motivational therapy then has
no value, plus 233 where social therapy dominates). As the
threshold increases, the motivational therapy becomes more
attractive because the possible health gains from the motiva-
tional therapy are more highly valued than the possible cost sav-
ings from the social therapy.When a QALY is worth £100 000 to
decision makers, the motivational therapy is preferable to the
social network therapy in 662 (66.2%) of the 1000 samples).
Between these two points, if decision makers value an additional
QALY at £30 000 (a value consistent with previous recommen-
dations made by the National Institute for Clinical Excellence in
the United Kingdom),22 then motivational enhancement therapy
has a 57.6% probability of being more cost effective than social
behaviour and network therapy, and the complementary
probability for social behaviour and network therapy is 42.4%.
Discussion
In the accompanying clinical paper on the UK alcohol treatment
trial, we concluded that social behaviour and network therapy (a
novel treatment for alcohol problems) was as effective as motiva-
tional enhancement therapy (a treatment of proven effective-
ness).9 Participants reported highly significant improvements in
drinking and associated problems, and in mental health. Our
economic analysis alongside the UK alcohol treatment trial
found no evidence of differences in net cost. Although the direct
cost of the social therapy was £92 per client more than that of the
motivational therapy, net savings in public sector resources,
including those devoted to health and social care and to criminal
justice, did not differ significantly between the two therapies—
both saved about five times as much as they cost.
We have carried out the first prospective cost effectiveness
analysis in alcohol research alongside a large multicentre
pragmatic randomised trial (the UK alcohol treatment trial). In
this analysis we estimated health gains and clients’ use of 40 dif-
ferent public services. Nevertheless we did not include loss of
productivity or measure the full social costs of either alcohol
related violence or the effects of alcohol problems on family or
friends; in particular we could not tell whether effects on family
and friends were increased or reduced by social behaviour and
network therapy. There was some evidence that using either
therapy increased time in employment. If we had not avoided
adding gains in productivity to gains in quality of life within eco-
nomic analysis, however, we would have counted benefits twice.14
The UK alcohol treatment trial reinforces the finding that
treatment for alcohol problems leads to net savings.23 24 We esti-
mated these savings by comparing clients’ use of services during
the six months before randomisation with their use during the
same period in the following year. If use of services before enter-
ing treatment is higher than normal, this technique may overes-
timate savings. In contrast, if the therapies each generate savings
during treatment25 or after 12 months, this technique may
underestimate savings. We did not attempt to model the long
term effects of reduced drinking on health.5
In the United Kingdom the National Institute for Clinical
Excellence seems to value an additional quality adjusted life year
(QALY) between £20 00015 and £30 000.22 Even if the value of a
QALY were £30 000, motivational enhancement therapy would
have 58% chance of being more cost effective than social behav-
iour and network therapy; by subtraction the social therapy
would have 42% chance of being more cost effective than the
motivational therapy. Participants allocated at random to the ref-
erence group received motivational enhancement therapy, a
treatment of proved effectiveness. Therefore the combination of
a sample size large enough to detect small differences and the
lack of significant differences leads to positive conclusions about
the value of both of these treatments for alcohol problems. In
particular we judge that our confidence intervals for differences
in utility and differences in cost exclude differences between the
therapies that would have led to unequivocal recommendations
in favour of one treatment.
In short we found evidence that social behaviour and
network therapy is as effective as motivational enhancement
therapy, and that both are cost effective. Thus commissioners of
treatment for alcohol problems are free to choose either or both






























































































At estimated incremental cost effectiveness ratio of £18 230,
probability that motivational enhancement therapy is cost
effective relative to social behaviour and network therapy is
0.486
When decision maker is willing to pay £30 000 for QALY, 21
probability is 0.576
    
Cost effectiveness acceptability curve for motivational enhancement therapy
relative to social behaviour and network therapy
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treatments on the basis of local circumstances, notably the avail-
ability of therapists of each type in statutory and non-statutory
services. Although both treatments give value for money, both
need trained therapists. We found that training is feasible and
cheap. Hence there is now strong evidence about the
effectiveness and cost effectiveness of two complementary treat-
ments for alcohol problems.
Continuing analysis of the UK alcohol treatment trial data
will focus on the crucial question whether we can characterise
who respond better to motivational enhancement therapy than
to social behaviour and network therapy and vice versa, and thus
achieve even greater benefits from each treatment at no
additional cost.
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What is already known on this topic
Studies suggest that psychosocial treatment for alcohol
problems is cost effective, yet many have methodological
weaknesses
What this study adds
Social behaviour and network therapy did not differ
significantly in cost effectiveness from motivational
enhancement therapy
Both therapy groups reported substantially reduced drinking
and associated problems and achieved large savings in the
costs of health and social care and of criminal justice
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